mAbLogix™ is our proprietary cell-based platform that derives human antibodies using a fully in vitro system. This process involves construction of human B-cell libraries, which are then screened against a chosen antigen. Our discovery process is differentiated by the large size of human B-cell libraries generated and by the rapid, cell-based screening process. Together, these capabilities allow us to quickly explore the entire human antibody repertoire and generate fully human monoclonal antibodies (mAbs) against diverse antigens.
In conjunction with LEAP® instrumentation, the mAbLogix™ antibody discovery process is shortened and optimized to avoid the limitations of other, animal-derived antibody discovery methods. mAbs have become important in targeting therapeutics against cancer cells, viruses, bacteria and toxins – and also in targeting autoimmune diseases such as diabetes, lupus, rheumatoid arthritis and multiple sclerosis.